Answers are grounded in this paper and cite their sources.
Randomized trial evaluates prognostic blood tests to enhance survival in patients with advanced cancer, suggesting potential benefits for elderly individuals.
e16348 Background: Prognostic blood tests (PBTs) are independent predictors of survival and often outperform traditional clinical prognostic characteristics (CPCs). Low-dose chemotherapy may safely prolong survival in patients with a performance status of 0-2. Methods: Consecutive patients with advanced stage IV pancreatic cancer and performance status 0–2, either treatment-naïve or previously treated with 2 (1-3) standard multi-drug regimens, were administered one-third standard doses of gemcitabine and FOLFIRINOX. Upon progression, docetaxel and mitomycin C were added. Survival was evaluated using Kaplan–Meier and Cox regression analyses. Predefined cut points included age (> 70, > 65 years) and baseline PBTs, summarized by the A.L.A.N. score (0–2 favorable vs ≥3 unfavorable), incorporating serum albumin ( < 3.5 g/dL), neutrophil-to-lymphocyte ratio (> 3), lymphocyte-to-monocyte ratio ( < 2.1), and absolute neutrophil count ( > 8). Ideal cut points (ICP) were also assessed. All patients provided written informed consent, with IRB approval, FDA, and ClinicalTrials.gov registration. Results: Across all ages, favorable PBT subgroups comprised 70–85% of patients, including 53 treatment-naïve and 53 previously treated individuals. Median survival times ranged from 12 to 20 months, with 2-year survival rates of 20–38%, and no hospitalizations, treatment-limiting toxicities, or withdrawals. Median survival for patients aged < 70 versus ≥70 years, 40 patients, was 12.5 versus 12.8 months, with 2-year survival of 21.4% versus 27.5% (p = 0.36). For patients aged < 65 versus ≥65 years, 66 patients, median survival was 12.1 versus 12.6 months, with 2-year survival of 16% versus 30% (p = 0.056). PBTs demonstrated strong prognostic significance: A.L.A.N. score (p < 10⁻⁹), serum albumin (p < 10⁻⁷), absolute neutrophil count (p < 10⁻⁶), neutrophil-to-lymphocyte ratio (p < 10⁻³), and lymphocyte-to-monocyte ratio (p = 0.04). Ideal cut points further strengthened associations. No interaction was observed between age and individual PBTs (p = 0.44). Conclusions: Independent of age (55–80 years), or unfavorable PBTs, A.L.A.N. scores of 0–2 identify a substantial subset of patients, including a potentially doubling proportion of elderly individuals, with actionable survival exceeding 12 months and excellent safety using economical low-dose chemotherapy. Systematic archiving and use of PBTs may expand opportunities for geriatric oncology research, including treatment safety, substantially sparing hospitalizations, low-dose strategies, recombination and rechallenge approaches, enhanced geriatric evaluation tools, and targeted investigation of immune-mediated or host-cell resistance mechanisms. Clinical trial information: 119005 .
No takes yet. Share an insight, caveat, or question.
Jager et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: